Matinas BioPharma Holdings Inc (MTNB) Short Interest Update

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 1,873,864 shares, a decline of 6.2% from the November 15th total of 1,998,494 shares. Based on an average trading volume of 173,935 shares, the short-interest ratio is currently 10.8 days. Approximately 2.6% of the company’s shares are short sold.

Separately, ValuEngine lowered Matinas BioPharma from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th.

An institutional investor recently bought a new position in Matinas BioPharma stock. Yellowstone Partners LLC purchased a new stake in shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 143,914 shares of the company’s stock, valued at approximately $190,000. Yellowstone Partners LLC owned 0.16% of Matinas BioPharma at the end of the most recent reporting period.

Shares of Matinas BioPharma (NYSEAMERICAN:MTNB) opened at $1.48 on Friday. Matinas BioPharma has a 52 week low of $1.01 and a 52 week high of $3.99.

Matinas BioPharma (NYSEAMERICAN:MTNB) last released its earnings results on Wednesday, November 15th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Matinas BioPharma had a negative return on equity of 195.09% and a negative net margin of 7,558.92%. The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.05 million.

COPYRIGHT VIOLATION NOTICE: “Matinas BioPharma Holdings Inc (MTNB) Short Interest Update” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

What are top analysts saying about Matinas BioPharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Matinas BioPharma and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit